RRMS Patients Needed for Phase 3 Trial to Assess Adverse GI Effects of ALKS 8700 Therapy vs. Tecfidera

August 28, 2017 /
MS Research Study and Reports

                                                                  

  
Click here to receive MS news via e-mail



Alkermes is
funding a Phase 3 clinical trial evaluating the effects of its ALKS
8700 therapy on the gastrointestinal tracts of relapsing-remitting
multiple sclerosis (RRMS) patients, compared to Tecfidera (dimethyl
fumarate), according to a news release by the National Multiple Sclerosis
Society. ALKS 8700, an orally administrated form of monomethyl fumarate,
is still under clinical development. Although similar to Tecfidera, ALKS 8700
[…]




MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 
Join us, opt-in here: www.register.msviewsandnews.org 
…………………………
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews

Stay informed with MS news and information - Sign-up here

For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT

Share:

Categories

Latest Blog Posts